Adiponectin and Insulin Sensitivity in Primary Aldosteronism

American Journal of Hypertension

Volumn 20, Issue 8, 2007, Pages 855-861

  Fallo, Francesco ^a   Della Mea, Paolo ^a   Sonino, Nicoletta ^a   Bertello, Chiara ^b   Ermani, Mario ^a   Vettor, Roberto ^a   Veglio, Franco ^b   Mulatero, Paolo ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Adiponectin; insulin resistance; primary aldosteronism

Indexed keywords

ADIPONECTIN; INSULIN; POTASSIUM;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ESSENTIAL HYPERTENSION; FEMALE; HOMEOSTASIS; HUMAN; HYPOKALEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; METABOLIC SYNDROME X; POTASSIUM BLOOD LEVEL; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL;

ADIPONECTIN; ALDOSTERONE; BIOLOGICAL MARKERS; CHEMILUMINESCENT MEASUREMENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERALDOSTERONISM; INSULIN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POTASSIUM; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; RADIOIMMUNOASSAY; REGRESSION ANALYSIS; RISK FACTORS;

EID: 34547443383     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2007.03.012     Document Type: Article

References (31)

1. Reaven G.M. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 88 (2003) 2399-2403
2. Shamiss A., Carroll J., and Rosenthal T. Insulin resistance in secondary hypertension. Am J Hypertens 10 (1992) 755-759
3. Corry D.B., and Tuck M. The effect of aldosterone on glucose metabolism. Curr Hypertens Rep 5 (2003) 106-109
4. Skrha J., Haas T., Šindelka G., Prazny M., Widimský J.R., Cibula D., and Svacina S. Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICKI indexes in subjects with different endocrine disorders. J Clin Endocrinol Metab 89 (2004) 135-141
5. Catena C., Lapenna R., Baroselli S., Nadalini E., Colussi G.L., Novello M., Favret G., Melis A., Cavarape A., and Sechi L.A. Insulin sensitivity and primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 91 (2006) 3457-3463
6. Giacchetti G., Ronconi V., Turchi F., Agostinelli L., Mantero F., Rilli S., and Boscaro M. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens 25 (2007) 177-186
7. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
8. Fallo F., Veglio F., Bertello C., Sonino N., Della Mea P., Ermani M., Rabbia F., Federspil G., and Mulatero P. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 91 (2006) 454-459
9. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith S.C., Spertus J.A., and Costa F. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
10. Milliez P., Girerd X., Plouin P.F., Blacher J., Safar M.E., and Mourad J.J. Evidence of an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45 (2005) 1243-1248
11. Giacchetti G., Sechi L.A., Rilli S., and Carey R.M. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 16 (2005) 120-125
12. Goldstein B.J., and Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 89 (2004) 2563-2568
13. Vettor R., Milan G., Rossato M., and Federspil G. Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther 22 Suppl 2 (2005) 3-10
14. Santaniemi M., Antero Kesaniemi Y., and Ukkola O. Low plasma adiponectin concentration is an indicator of the metabolic syndrome. Eur J Endocrinol 155 (2006) 745-750
15. Della Mea P., Lupia M., Bandolin V., Guzzon S., Sonino N., Vettor R., and Fallo F. Adiponectin, insulin resistance, and left ventricular structure in dipper and nondipper essential hypertensive patients. Am J Hypertens 18 (2005) 30-35
16. Patel J.V., Lim E.A., Hughes E.A., and Lip G.Y.H. Adiponectin and hypertension: a putative link between adipocyte function and atherosclerotic risk?. J Hum Hypertens 21 (2007) 1-4
17. Mulatero P., Dluhy R.G., Giacchetti G., Boscaro M., Veglio F., and Stewart P.M. Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol Metab 16 (2005) 114-119
18. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26 Suppl 1 (2003) S5-S20
19. Mulatero P., Rabbia F., Milan A., Taglieri C., Morello F., Chiandussi L., and Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 40 (2002) 897-902
20. Stas S., Appesh L., and Sowers J. Metabolic safety of antihypertensive drugs: myth versus reality. Curr Hypertens Rep 8 (2006) 403-408
21. Mulatero P., Milan A., Fallo F., Regolisti G., Pizzolo F., Fardella C., Mosso L., Marafetti L., Veglio F., and Maccario M. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab 91 (2006) 2618-2623
22. Engeli S. Role of the renin-angiotensin-aldosterone system in the metabolic syndrome. Contribut Nephrol 151 (2006) 122-134
23. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and β cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 23 (1985) 412-419
24. Lansang M.C., Williams G.H., and Carroll J.S. Correlation between the glucose clamp technique and the homeostasis model assessment in hypertension. Am J Hypertens 14 (2001) 51-53
25. Blalock H.M. Social Statistics (1972), McGraw-Hill, New York 406-407 Chapter 18: Correlation and regression (IT)
26. Fallo F., Scarda A., Sonino N., Paoletta A., Boscaro M., Pagano C., Federspil G., and Vettor R. Effect of glucocorticoids on adiponectin: a study in healthy subjects and in Cushing's syndrome. Eur J Endocrinol 150 (2004) 339-344
27. Henquin J.C. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49 (2000) 1751-1760
28. Baker A.R., da Silva N.F., Quinn D.W., Harte A.L., Pagano D., Bonser R.S., Kumar S., and McTernan P.G. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol 5 (2006) 1-7
29. Rossi G.P., Boscaro M., Ronconi V., and Funder J.W. Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab 16 (2005) 104-107
30. Ohashi K., Kihara S., Ouchi N., Kumada M., Fujita K., Hiuge A., Hibuse T., Ryo M., Nishizawa H., Maeda N., Maeda K., Shibata R., Walsh K., Funahashi T., and Shimomura I. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 47 (2006) 1108-1116
31. Kurtz T.W. New treatment strategies for patients with hypertension and insulin resistance. Am J Med 119 5 Suppl 1 (2006) S24-S30